Free Trial Information
BioCentury | Oct 6, 2018
Finance

Seeking validation

...NASDAQ:SBPH) Inarigivir soproxil Chronic HBV Additional Ph II ACHIEVE data November TherapeuticsMD Inc. (NASDAQ:TXMD) TX-001HR estradiol/progesterone...
Read More
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...TGTX-1101) Chronic lymphocytic leukemia (CLL) Top-line Ph III UNITY-CLL trial 2H18 TherapeuticsMD Inc. (NASDAQ:TXMD) TX-001HR estradiol/progesterone...
Read More
BioCentury | Jan 5, 2018
Clinical News

TherapeuticsMD submits NDA for TX-001HR to treat menopause symptoms

...TherapeuticsMD Inc. (NYSE-M:TXMD) submitted an NDA to FDA for TX-001HR estradiol/progesterone to treat moderate to severe...
...TherapeuticsMD Inc. (NASDAQ:TXMD), Boca Raton, Fla. Product: Estradiol/progesterone (TX-001HR) (formerly TX 12001-HR) Business: Endocrine/Metabolic Elizabeth S. Eaton estradiol/progesterone TX-001HR TherapeuticsMD...
Read More
BioCentury | Dec 21, 2017
Translation in Brief

Replacing the replacements

A Wake Forest team has developed a cell-based hormone replacement therapy that can control the hypothalamic-pituitary-ovarian axis with lower levels of estrogen than standard therapies, and could provide a solution to the side effects of...
Read More
BioCentury | Sep 27, 2017
Financial News

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

...13%) to $5.28, and Newron slipped CHF1.55 (10%) to CHF14.35. GTx added $0.01 to $8.78. Jennie Walters EMD-128130 estradiol/progesterone Evenamide NW-3509 sarizotan tesevatinib TX-001HR TX-004HR Yuvvexy GTx...
Read More
BioCentury | Feb 23, 2017
Clinical News

TX-001HR: Ph III Replenish data

...menopause showed that once-daily 1 mg/100 mg and 0.5 mg/100 mg doses of oral TX-001HR estradiol/progesterone...
...dose of TX-001HR. TherapeuticsMD Inc. (NYSE-M:TXMD), Boca Raton, Fla. Product: Estradiol/progesterone ( TX-001HR ) (formerly TX 12-001-HR...
...Menopause-Specific Quality of Life (MENQOL) and safety Status: Phase III data Milestone: Submit NDA (3Q17) Chris Lieu TX-001HR TherapeuticsMD...
Read More
BioCentury | Oct 3, 2016
Finance

ASH and others

...NYSE:TEVA) SD-809 deutetrabenazine Moderate to severe tardive dyskinesia Submit NDA YE16 TherapeuticsMD Inc. (NYSE-M:TXMD) Estradiol/progesterone (TX-001HR...
Read More
BioCentury | Nov 2, 2015
Clinical News

Estradiol/progesterone: Completed Phase III enrollment

...TherapeuticsMD Inc. (NYSE-M:TXMD), Boca Raton, Fla. Product: Estradiol/progesterone ( TX-001HR ) (formerly TX 12-001-HR ) Business: Endocrine/Metabolic...
...40-65 in the double-blind, placebo-controlled, U.S. Phase III REPLENISH trial evaluating 4 doses of once-daily TX-001HR...
Read More
BioCentury | Jul 31, 2014
Financial News

TherapeuticsMD raises $40 million in follow-on

Women's healthcare company TherapeuticsMD Inc. (NYSE:TXMD) raised $40 million through the sale of 8.6 million shares at $4.67 in a follow-on underwritten by Goldman Sachs and Noble Capital Markets. TherapeuticsMD proposed the follow-on late Tuesday,...
Read More
BioCentury | Jul 30, 2014
Financial News

TherapeuticsMD proposes $40 million follow-on

Women's health company TherapeuticsMD Inc. (NYSE-M:TXMD) proposed late Tuesday to raise $40 million in a follow-on underwritten by Goldman Sachs and Noble Capital Markets. TherapeuticsMD is developing a pipeline of hormone therapy products for menopause-related...
Read More
Items per page:
1 - 10 of 11